DE602004013165D1 - Chimärisches vektorsystem - Google Patents

Chimärisches vektorsystem

Info

Publication number
DE602004013165D1
DE602004013165D1 DE602004013165T DE602004013165T DE602004013165D1 DE 602004013165 D1 DE602004013165 D1 DE 602004013165D1 DE 602004013165 T DE602004013165 T DE 602004013165T DE 602004013165 T DE602004013165 T DE 602004013165T DE 602004013165 D1 DE602004013165 D1 DE 602004013165D1
Authority
DE
Germany
Prior art keywords
vector
siv
chimarical
vector system
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004013165T
Other languages
English (en)
Other versions
DE602004013165T2 (de
Inventor
Andrew Michael Lindsay Lever
Padraig Michael Strappe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of DE602004013165D1 publication Critical patent/DE602004013165D1/de
Application granted granted Critical
Publication of DE602004013165T2 publication Critical patent/DE602004013165T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Complex Calculations (AREA)
  • Feedback Control In General (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Devices For Executing Special Programs (AREA)
  • Image Analysis (AREA)
  • Control Of Ac Motors In General (AREA)
DE602004013165T 2003-08-08 2004-08-09 Chimärisches vektorsystem Active DE602004013165T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0318704 2003-08-08
GBGB0318704.4A GB0318704D0 (en) 2003-08-08 2003-08-08 Chimaeric vector system
PCT/GB2004/003438 WO2005014836A2 (en) 2003-08-08 2004-08-09 Chimaeric vector system

Publications (2)

Publication Number Publication Date
DE602004013165D1 true DE602004013165D1 (de) 2008-05-29
DE602004013165T2 DE602004013165T2 (de) 2009-04-30

Family

ID=27839918

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004013165T Active DE602004013165T2 (de) 2003-08-08 2004-08-09 Chimärisches vektorsystem

Country Status (7)

Country Link
US (1) US8298826B2 (de)
EP (1) EP1660665B1 (de)
AT (1) ATE392482T1 (de)
DE (1) DE602004013165T2 (de)
ES (1) ES2305840T3 (de)
GB (1) GB0318704D0 (de)
WO (1) WO2005014836A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170431A2 (en) * 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems
KR101811736B1 (ko) 2011-09-26 2017-12-22 떼라벡띠스 렌티바이러스 패키징을 위한 비-서브타입 b gag 단백질의 용도
JP2015514130A (ja) * 2012-04-10 2015-05-18 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ バキュロウイルスベクターを用いる膀胱癌の治療法
WO2015069469A1 (en) 2013-11-05 2015-05-14 Clontech Laboratories, Inc. Dry transfection compositions and methods for making and using the same

Also Published As

Publication number Publication date
US8298826B2 (en) 2012-10-30
GB0318704D0 (en) 2003-09-10
ATE392482T1 (de) 2008-05-15
ES2305840T3 (es) 2008-11-01
US20070184025A1 (en) 2007-08-09
EP1660665B1 (de) 2008-04-16
WO2005014836A2 (en) 2005-02-17
WO2005014836A3 (en) 2005-06-02
DE602004013165T2 (de) 2009-04-30
EP1660665A2 (de) 2006-05-31

Similar Documents

Publication Publication Date Title
YU79092A (sh) Direktno molekularno klonirnje modofikovanog eukariotičnog citoplazmatičnog dnk virusnog genoma
Lee et al. Robust and persistent SARS-CoV-2 infection in the human intestinal brush border expressing cells
CY1113241T1 (el) Μεθοδος για την παραγωγη ενεργου συστατικου ενος φαρμακευτικου ή διαγνωστικου μεσου εντος καλλιεργειας αιωρηματος κυτταρων mdck
UA85536C2 (en) Viral antigens
CY1110525T1 (el) Βελτιστοποιημενη εκφραση της hpv 45 li σε ζυμη
EP2359851A3 (de) MVA-exprimierende modifizierte HIV-Hüll-, GAG- und POL-Gene
WO2004055161A3 (en) Large scale production of packaged alphavirus replicons
Chen et al. Cytoplasmic tail truncation of SARS-CoV-2 spike protein enhances titer of pseudotyped vectors but masks the effect of the D614G mutation
DE60141014D1 (de) Verfharen zur herstellung von herpes-simplex-virus-amplikons, die resultierenden amplikons und ihre verwendung
Gwon et al. N-glycosylation in the pre-membrane protein is essential for the Zika virus life cycle
AU2001275438A1 (en) Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
Gonzalez et al. Identification of domains in the simian immunodeficiency virus matrix protein essential for assembly and envelope glycoprotein incorporation
DE602004013165D1 (de) Chimärisches vektorsystem
Bour et al. Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release
Giron et al. Human foamy virus polypeptides: identification of env and bel gene products
BUKRINSKAYA et al. HIV-1 matrix protein p17 resides in cell nuclei in association with genomic RNA
Manrique et al. Mutational analysis of the feline immunodeficiency virus matrix protein
WO2003031583A3 (en) Generation of virus-like particles by vsv
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
DK1334197T3 (da) Gær-afledt vaccine mod IPNV
Dolskiy et al. Increased LAMP1 expression enhances SARS-CoV-1 and SARS-CoV-2 production in Vero-derived transgenic cell lines
Tallmadge et al. Development and characterization of an equine infectious anemia virus Env-pseudotyped reporter virus
PT1383796E (pt) Estirpe neurovirulenta do vírus do nilo ocidental e as suas aplicações
Bell Pathogen evolution within host individuals as a primary cause of senescence
EP1309342A4 (de) Herstellung eines chimeren papillomavirus(22.01.2)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition